Health AI Central
Peer-Reviewed Publication
Diabet Med2026;e70413.July 1, 2026Journal Article

Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.

Edwin W D'Souza1, Jessica R Castle2, Kimia Z Assadi1, Laurel H Messer1, Jordan E Pinsker1
1Medical Affairs, Tandem Diabetes Care, San Diego, California, USA.
2Medical Affairs, Dexcom, Inc., San Diego, California, USA.
PubMed DOI

Abstract

BACKGROUND: Real-world performance of the Tandem Mobi insulin pump with Control-IQ+ technology has been evaluated in small early access studies, but data from larger populations with long-term use has yet to be presented, especially with the use of newer sensors and newly indicated populations. METHODS: The Tandem Mobi insulin pump with Control-IQ+ technology paired with the Dexcom G7 continuous…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.